Jnana Therapeutics is creating therapies to treat a wide variety of diseases by uncovering and targeting unique binding sites of highly validated protein targets. Chemoproteomics is facilitating drug discovery for previously inaccessible protein targets. Jnana has built a next-generation chemoproteomics platform, RAPID, to develop small molecule medicines for any target with unprecedented speed and efficiency. This approach is enabling Jnana to address a range of challenging target classes including SLC transporters, transcription factors and signaling scaffold proteins that are significant drivers of disease. Their lead candidate, JNT-517, is targeting a SLC transporter that plays a role in PKU.

<p>Jnana Therapeutics specializes in discovering and developing medicines to expand the universe of therapeutic impact. By combining deep drug discovery, development expertise and their proprietary technology, Jnana is unlocking highly validated but previously undruggable targets. Drug discovery involves use of Jnana’s chemoproteomic platform, Reactive Affinity Probe Interaction Discovery (RAPID), a proprietary ligand platform to identify small molecule binders irrespective of the target. The unbiased approach of RAPID allows challenging targets, such as transcription factors and helicases, to be investigated. By using their RAPID platform, Jnana is developing a pipeline targeting many rare genetic diseases, immune-mediated diseases and oncology.  </p>


Jnana Therapeutics

Scientist I/II, Early Discovery Biology

Director, Toxicology

Don't see a perfect job? Apply opportunistically.



		
			
				Sep 06, 2023
							
		

		
			Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
		

	

Jnana Therapeutics discovers new SLC6A19 inhibitors - BioWorld MedTech

Roche backs Jnana quest to drug SLC transporters with $40M down payment - BioWorld MedTech

Today, we presented clinically meaningful, statistically significant results from the second-dose cohort of the Phase 1/2 clinical trial of JNT-517 in adults with phenylketonuria (PKU) at the Society for the Study of Inborn Errors of Metabolism 2024 Annual Symposium.

Based on these positive results, we plan to advance JNT-517 directly into a pivotal Phase 3 study in early 2025. Read more: https://bit.ly/47fmynI

#SSIEM24 #clinicaltrials #raredisease #PKU


Jnana Therapeutics to Participate in Upcoming Investor Conferences - Business Wire


								Aug 01, 2024
								Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
							

Jnana tops up with $107M series C, $2B Roche deal ...

We’re hiring! Interested in applying your knowledge and curiosity to advance drug discovery programs for challenging diseases? Check out our open positions at https://lnkd.in/e6CjrvV3
#Hiring 
 
May 2025 01US25EUC0221

Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. - GlobeNewswire


              Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency
            

Phenylketonuria Market to Exhibit Significant Growth, - GlobeNewswire

BridGene nets another Takeda deal amid plans to raise more funding and go public - Endpoints News

 The Week’s 10 Biggest Funding Rounds: Health And Biotech Land Big Week As DispatchHealth Leads 


								Sep 23, 2024
								Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
							

 Roche backs Jnana quest to drug SLC transporters with $40M down payment 

Jnana reports topline data from Phase Ia trial of PKU therapy - Clinical Trials Arena



		
			
				Feb 01, 2024
							
		

		
			Jnana says pivotal trial of PKU pill could begin next year after promising results from a smaller study
		

	

 Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference 

Updated: Otsuka buys out small molecule drug discovery startup Jnana and its rare disease pill for $800M cash - Endpoints News

Skadden, Latham & Watkins steer USD1.12bn biotech sale - Law.asia

Startup Jnana raises $50M to tackle elusive membrane protein targets - Fierce Biotech

Attending #SSIEM24? Join us on Thursday, Sept 5, for a symposium on the potential for SLC6A19 inhibition as a treatment approach for PKU and other amino acid disorders. 

We’re looking forward to hearing from presenters Cary O. Harding, MD, Nicola Longo, MD, Ania C. Munta, MD, and John Throup, PhD. 

Details here: https://bit.ly/3yTChfz #SSIEM #clinicaltrials #PKU

Investors Launch Biotech Startup Jnana Therapeutics With $50 Million - WSJ

Maze Therapeutics discovers new SLC6A19 inhibitors - BioWorld Online

Jnana deepens ties with Roche and grabs a new round of funding - BioPharma Dive

Phenylketonuria (PKU) is one of many rare genetic diseases that are diagnosed in childhood. There continues to be a critical need for a safe and efficacious treatment for PKU, which can cause progressive and severe neurological impairment and neuropsychological complications. 

At Jnana, we are currently advancing JNT-517 as a potential first-in-class oral treatment for PKU. Learn more about our clinical studies: https://bit.ly/41h4dUQ #RareDiseaseDay


We are proud to announce that Jnana Therapeutics is now part of Otsuka Pharmaceutical Co., Ltd. Jnana will continue to be based in Boston and operate as a direct subsidiary of Otsuka America, Inc. 

We look forward to continuing our mission to develop small molecules against challenging-to-drug targets for under-addressed diseases and advancing JNT-517 into a pivotal Phase 3 study for PKU in early 2025. Read more: https://bit.ly/3ZD6b2q
 
#acquisition #pharmaceuticals #biotechnology 

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership - Labiotech.eu

 Jnana closes $50M series B round, picks PKU as lead indication 

 Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche 

Otsuka pays $800M for Jnana Therapeutics and its clinical-stage PKU drug - Fierce Biotech

Jnana Therapeutics tries to take on an untapped class of proteins - Chemical & Engineering News

Skadden, Latham act on $1.1 bln Japan outbound pharma deal - Legal Business Online

 Roche, Jnana take aim at metabolite transporters in $40M discovery deal 



		
			
				Sep 23, 2024
							
		

		
			Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
		

	

 Naphthyl-containing piperidine inhibitors of slc6a19 function 

Roche Doubles Down on Jnana’s RAPID Platform in $2B Deal (Updated) - BioSpace

Neurocrine, Jnana team up to discover CNS drugs - Fierce Biotech

Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Japan's Otsuka Pharma acquires American biotech startup Jnana Therapeutics for $1.1 B - BSA bureau

Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU - Yahoo Finance

Otsuka buys Jnana and PKU drug in $1.1bn deal - pharmaphorum

Jnana tops up with $107M series C, $2B Roche deal as it pushes metabolic asset into clinic - Fierce Biotech

Jnana closes $107M series C round, banks $50M up front in second discovery Roche pact - BioWorld MedTech

Japan’s Otsuka Pharma to pay up to $1.1-billion to acquire Jnana Therapeutics - The Globe and Mail

Jnana Therapeutics Appoints Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer - citybiz

 Jnana Therapeutics Raises $107M in Series C Funding 

Japan's Otsuka Pharma acquires American biotech startup Jnana Therapeutics for $1.1 B - BioSpectrum Asia

Otsuka Pharmaceutical to Acquire Jnana Therapeutics for $800M - Contract Pharma

Jnana Therapeutics to Present Preclinical Data on its PKU Program at the 2023 Society for Inherited Metabolic Disorders Annual Meeting - Business Wire

As we close PKU Awareness Month, we are reminded that there remains a tremendous need for new treatments for phenylketonuria (PKU). Jnana is committed to advancing clinical research to meet the critical needs of PKU patients.

May 2025 01US25EUC0241


PKU is a rare, inherited metabolic disease that can cause progressive and severe neurological impairment and neuropsychological complications. There’s a critical need for a safe and efficacious treatment for individuals with PKU. This year, International PKU Day focuses on raising awareness about the lives of adults with PKU. 

Find out more at: https://www.espku.org/ #PKU #adultPKUawareness #PKUDAY2024 

We’re at the E.S. PKU (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria) Conference this week. Stop by our exhibit table, and don’t miss our poster presentation featuring data on the efficacy and safety of JNT-517 from our Phase 1/2 study in adults with PKU. #ESPKU2024

Jnana Therapeutics describes new SLC6A19 inhibitors - BioWorld Online

Otsuka to buy Jnana in deal that may exceed $1 billion - The Pharma Letter

Jnana doses first subject in phenylketonuria therapy trial - Clinical Trials Arena

Jnana Therapeutics - The Pharma Letter

 Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer 

Jnana Therapeutics inks second collaboration with Swiss giant - The Pharma Letter

 New SLC6A19 inhibitors divulged in Jnana Therapeutics patents 

Otsuka to buy Boston chemoproteomics biotech for up to $1.1B - BioWorld Online

 Jnana Therapeutics Closes $50M Series B Financing 

Big Pharma-backed startup scores $107M, second Roche collab - The Business Journals

Otsuka buys startup Jnana, adding to uptick in private biotech M&A - BioPharma Dive

 Jnana Therapeutics inks second collaboration with Swiss giant 

Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer - citybiz

Pfizer backs this women-led biotech in $107M Series C to develop pills for cancer, neurological diseases and rare disorders - Tech Funding News 

We're looking forward to joining Otsuka Pharmaceutical Companies (U.S.) at the 2025 ACMG - American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. 

Jnana Therapeutics to Advance JNT-517 as Development Candidate and Potential First-in-Class Oral Treatment for PKU - Business Wire

Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases - PR Newswire

Jnana Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Roche, Jnana take aim at metabolite transporters in $40M discovery deal - Fierce Biotech

Watkins Advises Jnana Therapeutics in Acquisition by Otsuka Pharmaceutical - Latham & Watkins LLP

Bain closes $3B biotech fund amid flurry of startup buyouts - BioPharma Dive

 Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. 

Neurocrine, Jnana team up to discover CNS drugs

 Phenylketonuria Treatment Market Set to Surge at 7.8% CAGR, to Reach US$ 1.62 Billion by 2034: Fact.MR Report 



		
			
				May 10, 2024
							
		

		
			Freeline, Wugen & Jnana Secure EMA PRIME Designations For Novel Treatments
		

	

Jnana Therapeutics Presents New Positive Data from Phase - GlobeNewswire

Otsuka snaps up Jnana with its phenylketonuria drug for $800m - Pharmaceutical Technology

SLC6A19 inhibitors disclosed in Jnana Therapeutics patent - BioWorld Online

 Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class ... 

 Healthcare And AI Sectors Continue To Lead, While Funding Settles In July 2024 

Otsuka Agrees To Acquire Jnana Therapeutics - Contract Pharma

 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION 

 Jnana Therapeutics Announces Appointment of John Throup, Ph.D. as Senior Vice President, Head of Development 

 SLC6A19 inhibitors disclosed in Jnana Therapeutics patent 

Boston biotech Jnana raises $107 million and strikes second collaboration with Roche - The Boston Globe

 Dosing regimen for treating pku with a piperidine inhibitor of slc6a19 function 

Jnana Therapeutics announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical Co.

By bringing together the strength of Jnana’s RAPID platform with Otsuka’s global capabilities and resources, the proposed transaction will further enable the development of novel therapies for under-addressed diseases, including JNT-517 for PKU.

Upon completion of the acquisition later this year, Jnana will operate as a wholly owned subsidiary of Otsuka in Boston and continue its research and development.

Read more: https://bit.ly/4ftndW9 #biotechnology #biopharma #acquisition

Jnana Therapeutics Promotes Joel Barrish, Ph.D., to President - citybiz

Jnana Therapeutics Launches With $50 Million Series A Financing to Target the Cell’s Metabolic Gates - Business Wire

FierceBiotech names Jnana Therapeutics as one of its “Fierce 15” Biotech Companies of 2018 - Business Wire

Jnana closes $50 million financing to advance lead PKU program - The Pharma Letter

Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics - ET HealthWorld

 Crystalline forms of a piperidine inhibitor of slc6a19 function 

Roche, Jnana take aim at metabolite transporters in $40M ...

Thanks to Dean Brown, Ph.D., and Heike Wobst, Ph.D., for their leadership at this week’s Drug Discovery Chemistry conference.

Dean is facilitating a breakout discussion as part of the Fragment-Based Drug Discovery Best Practices & Innovations session. Heike is chair of the Degrader Approaches for KRAS session.

More about the conference here: https://lnkd.in/gkhkep5 #DrugDiscoveryChemistry Only registered participants of the Drug Discovery Chemistry Conference are eligible to attend as determined by the event organizer. Jnana has no control over registration, or the fees associated.
April 2025 01US25EUP0016

Otsuka to acquire US-based Jnana Therapeutics for up to $1.1bn - World Pharmaceutical Frontiers

Jnana Therapeutics

Business:

Drug notes:

About: